Online inquiry

IVTScrip™ mRNA-Anti-C5, LFG 316(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10265MR)

This product GTTS-WQ10265MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets C5 gene. The antibody can be applied in Choroiditis, Age-related macular degeneration (AMD) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001317163.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 727
UniProt ID P01031
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-C5, LFG 316(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ10265MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8065MR IVTScrip™ mRNA-Anti-CD33, h2H12ec(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA h2H12ec
GTTS-WQ8944MR IVTScrip™ mRNA-Anti-IL1RL2, IL2 fused to diphteria toxin(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA IL2 fused to diphteria toxin
GTTS-WQ10726MR IVTScrip™ mRNA-Anti-FCGRT, M-281(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA M-281
GTTS-WQ12813MR IVTScrip™ mRNA-Anti-MASP2, OMS721(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA OMS721
GTTS-WQ10612MR IVTScrip™ mRNA-Anti-PDCD1, LY3300054(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA LY3300054
GTTS-WQ14655MR IVTScrip™ mRNA-Anti-DPEP3, SC-003 mAb(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SC-003 mAb
GTTS-WQ5505MR IVTScrip™ mRNA-Anti-IL6, CDP 6038(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CDP 6038
GTTS-WQ6295MR IVTScrip™ mRNA-Anti-CD274, CS-1001(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CS-1001
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW